US Panel Backs H. Lundbeck A/S Drug for Some Schizophrenics; FDA Ruling Expected by May 15
SILVER SPRING, Md., April 7 (Reuters) - A drug from H Lundbeck A/S is safe enough to win approval for some patients with schizophrenia despite concerns it may raise the risk of sudden death, a U.S. advisory panel said on Tuesday.